Belantamab mafodotin-blmf (Blenrep®) against BCMA, approved for blood cancer in 2020, was probably endocytosed clathrin-dependently by binding cell-surface BCMAs. This evidence concerns the gene TNFRSF17 and hematopoietic and lymphoid system neoplasm.